trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['destiny,lung,4', 't-dxd', 'lung', 'nsclc', 'destiny,lung02', 'sclc']
#esmo22 highlight: destiny-lung02 showed the rate of drug-related ild being lower in the t-dxd 5.4mg/kg arm vs the 6.4mg/kg arm, demonstrating a compelling positive benefit-risk balance for the use of t-dxd 5.4mg/kg in patients with her2m nsclc #noeticinsight 